At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 46 enrolled
Drug / intervention
Lithiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dysfunctional Cortico-Limbic Activity and Connectivity in Bipolar Disorder Before and After Lithium Treatment: An fMRI Study
In Brief
A Phase 4 clinical trial evaluating Lithium for Bipolar Disorder. Completed, enrolled 46 participants across 1 site.
Detailed Summary
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedJan 2008
Primary CompletionJan 2012
Study CompletionNov 2012
TodayJul 2026
First PostedJan 17, 2008
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.5 years ago
Interventions
Lithiumdrug
Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.